This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A First Look at the potential of Fezolinetant as a therapy for menopause and severe vasomotor symptoms (VMS)

Ticker(s): ALPMY

Who's the expert?

Institution: Inova Health

  • Assistant Professor of Medical Education at the University of Virginia; Operations Director for Quality of the Obstetrics and Gynecology Department at Inova Fairfax Medical Campus. 
  • Manages 30 patients a month with post-op pain.
  • Manages 220 patients with PPD
  • Special interest in the management of fibroids, abnormal uterine bleeding, permanent and nonpermanent contraception, and minimally-invasive gynecologic surgery.

Interview Goal
Discussing the potential of a new therapy in development, Astellas Pharma's Fezolinetant, an investigational non-hormonal selective neurokinin 3 (NK3) receptor antagonist.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.